AstraZeneca (AZN LN) - AZD1222 is effective against COVID-19; met primary endpoint. COVID-19 average efficacy 70.4% when combining data from two dosing regimes. Two different dosage regimes: one has ~90% efficacy.

• 
  90% efficacy is the approach which commences with a half dose followed by a full dose administered at least one month apart (2,741 participants) 


• 62% efficacy is the approach which has two full doses at least one month apart (8,895 participants)


• "independent Data Safety Monitoring Board determined that the analysis met its primary endpoint showing protection from COVID-19 occurring 14 days or more after receiving two doses of the vaccine."


• 
  Now immediately prepare the regulatory submission of data to global authorities
  


• The vaccine can be stored, transported & handled at normal fridge conditions (2-8 degrees Celsius) for at least 6-months
  


• Capacity of up to 3bln doses on a rolling basis in 2021


• Well tolerated across both dosing regimes


• Efficacy and safety data confirms it will be 'highly effective' against COVID-19


• Vaccine will be affordable


• Link to Release

Reaction details (07:10)

• In an immediate reaction European equity futures extended gains, DAX Dec'20 now +0.7%, FTSE +0.6%; mild selling pressure seen in Dec'20 Bund back to ~unchanged levels for the session. FX markets were less reactive.

Analysis details (07:15)

• 
  Pfizer's (PFE) vaccine had a 90% effective rate. Pfizer (PFE)/BioNTech (BNTX) candidate needed to be stored at -70 degrees celsius


• 
  Moderna (MRNA) Phase 3 vaccine efficacy rate 94.5%. Vaccine candidate expected to remains stable at standard fridge temperatures (2-8 degrees celsius) for 30-days. Shipping/long-term storage conditions at standard freezer temperatures of -20 degrees celsius for 6-months

23 Nov 2020 - 07:00- EquitiesImportant- Source: Newswires